VKTX

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric.

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.

Eli Lilly just posted a quarter that left its GLP-1 rivals in the dust, but margin pressure and a $900 million pile of one-time benefits raise questions about how much of that strength is real and how long it can last.

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.

Moby summary of Viking Therapeutics, Inc.'s Q3 2026 earnings call

Viking Therapeutics (VKTX) just posted third quarter results that widened its net loss, as spending on late stage obesity drug programs increased and investors weighed the updated launch timeline.

Viking Therapeutics (NASDAQ:VKTX) reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate, VK2735.

VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules.

CEO Brian Lian said a potential launch of obesity drug VK2735 remained about 2 and a half years away.

Investing.com -- Viking Therapeutics Inc (NASDAQ:VKTX) reported a third quarter loss that missed analyst expectations, as the company ramped up spending on its obesity drug development programs.